| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2803036801010 | 303680101 | RIVASTIGMINE/PHARMATHEN ORAL.SOL 2MG/ML BTx1 BOTTLEx50 ML | 11.45 | 12.01 | 16.55 |
| 05/2018 | 2803036801027 | 303680102 | RIVASTIGMINE/PHARMATHEN ORAL.SOL 2MG/ML BTx1 BOTTLEx120 ML | 26.73 | 28.04 | 38.64 |
For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.
Rivastigmine is a carbamate derivative that is structurally related to physostigmine, but not to donepezil and tacrine. The precise mechanism of rivastigmine has not been fully determined, but it is suggested that rivastigmine binds reversibly with and inactivates chlolinesterase (eg. acetylcholinesterase, butyrylcholinesterase), preventing the hydrolysis of acetycholine, and thus leading to an increased concentration of acetylcholine at cholinergic synapses. The anticholinesterase activity of rivastigmine is relatively specific for brain acetylcholinesterase and butyrylcholinesterase compared with those in peripheral tissues.
1.5 hours
Rivastigmine is extensively metabolized primarily via cholinesterase-mediated hydrolysis to the decarbamylated metabolite NAP226-90. Renal excretion of the metabolites is the major route of elimination. Less than 1% of the administered dose is excreted in the feces.
* 1.8 to 2.7 L/kg
* renal cl=2.1-2.8 L/hr